TABLE 2.
Bacterial strains used in this study
| Strain | Description | Source or reference(s) |
|---|---|---|
| E. coli | ||
| Top10 | F mcrA (mrr-hsdRMS-mcrBC) 80lacZM15 lacX74 recA1 deoR araD139 (ara-leu)7697 galU galK rpsL(Strr) endA1 nupG | Invitrogen |
| XL10 Ultracompetent Gold | endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte (mcrA)183 (mcrCB-hsdSMR-mrr)173 Tetr F' [proAB lacIqZM15 Tn10(Tetr Amyr Cmr)] | Agilent Technologies |
| NEB 5-alpha competent | fhuA2 Δ(argF-lacZ)U169 phoA glnV44 ϕ80Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 | New England BioLabs |
| N. gonorrhoeae | ||
| FA19 | Wild type | 76 |
| FA6747 | TbpA− (tbpA::mTn3cat) | 36, 40 |
| FA6815 | TbpAB− (ΔtbpB::Ω) | 38 |
| FA6905 | TbpB− (ΔtbpB) | 40 |
| MCV 192 | TbpA L3HΔ (T350–A361) | 25 |
| RSC 100 | TbpA D355P TbpB− (ΔtbpB) | This study |
| RSC 101 | TbpA D355P | This study |
| RSC 102 | TbpA A356P TbpB− (ΔtbpB) | This study |
| RSC 103 | TbpA A356P | This study |
| RSC 104 | TbpA N357P TbpB− (ΔtbpB) | This study |
| RSC 105 | TbpA N357P | This study |
| RSC 106 | TbpA Q358P TbpB− (ΔtbpB) | This study |
| RSC 107 | TbpA Q358P | This study |
| RSC 108 | TbpA K359P TbpB− (ΔtbpB) | This study |
| RSC 109 | TbpA K359P | This study |
| RSC 110 | TbpA Q360P TbpB− (ΔtbpB) | This study |
| RSC 111 | TbpA Q360P | This study |
| RSC 112 | TbpA K369P/Q360P TbpB− (ΔtbpB) | This study |
| RSC 113 | TbpA K369P/Q360P | This study |
| RSC 114 | TbpA N357P/Q358P/K359P/Q360P TbpB− (ΔtbpB) | This study |
| RSC 115 | TbpA N357P/Q358P/K359P/Q360P | This study |